Skip to main content
. 2015 Jun 22;48(2):546–552. doi: 10.4143/crt.2015.015

Fig. 1.

Fig. 1.

Progression-free survival (A) with first-line imatinib and overall survival (B) according to the type of PDGFRA mutation.